A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Trial Summary
This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: